Aurobindo Pharma Ltd updates on US FDA Inspection at Unit I & III of APL Healthcare Limited

Aurobindo Pharma Ltd's wholly owned subsidiary, APL Healthcare Limited's Unit I & III, an Orals (Tablets, Capsules and Soft gel Capsules) and Derma manufacturing facilities located at Jadcherla, Mahabub Nagar District, Telangana, which were inspected by the United States Food and Drug Administration from January 9 to January 18, 2023, have now been classified as Voluntary Action Indicated (VAI).

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 473.85 as compared to the previous close of Rs. 472.65. The total number of shares traded during the day was 26855 in over 1071 trades.

The stock hit an intraday high of Rs. 475.15 and intraday low of 468.00. The net turnover during the day was Rs. 12681555.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 APLHealthcare VAI ManufacturingFacilities Jadcherla USFDA Inspection VoluntaryActionIndicated